Literature DB >> 19158267

Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.

David J Litt1, Shona E Neal, Norman K Fry.   

Abstract

Pertussis (whooping cough) is a potentially fatal respiratory disease caused by the bacterium Bordetella pertussis. Despite effective vaccination programs, there has been concern in some developed countries that pertussis cases are on the increase. We characterized 703 clinical B. pertussis isolates collected in the United Kingdom between 1920 and 2006 using multilocus variable-number tandem repeat analysis (MLVA), pertactin (prnA) and pertussis toxin (ptxA) genotyping, and serotyping. The results showed that the genetic diversity of the bacterial population decreased during periods of high vaccine coverage. However, it was elevated between 1977 and 1986, when vaccine coverage in the United Kingdom was low and epidemics occurred. A high proportion of MLVA types during this epidemic period were novel, and the prnA(2) and prnA(3) alleles were seen for the first time in the United Kingdom. MLVA-27 appeared in 1982, was codominant during the 1998-to-2001 period, and comprised approximately 70% of isolates during both the 2002-to-2004 and the 2005-to-2006 periods. The United Kingdom is dominated currently by an MLVA-27 prnA(2) ptxA(1) serotype Fim3 clonal type. Even during recent periods dominated by MLVA-27, many novel types were found at low frequencies, suggesting that either there are a large number of uncommon MLVA types circulating at low frequencies or new types are constantly arising. This supports a hypothesis that MLVA-27 is under some form of positive selection conferring increased survival in a highly vaccinated population. There has been no significant change to the bacterial population in the first 2 years since the United Kingdom switched from a whole-cell to an acellular vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158267      PMCID: PMC2650949          DOI: 10.1128/JCM.01838-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Bordetella pertussis surveillance in England and Wales: 1995-7.

Authors:  P G Van Buynder; D Owen; J E Vurdien; N J Andrews; R C Matthews; E Miller
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

2.  Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.

Authors:  P Cassiday; G Sanden; K Heuvelman; F Mooi; K M Bisgard; T Popovic
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

3.  Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

Authors:  N K Fry; S Neal; T G Harrison; E Miller; R Matthews; R C George
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains.

Authors:  Natacha Kourova; Valérie Caro; Christian Weber; Sabine Thiberge; Raisa Chuprinina; Galina Tseneva; Nicole Guiso
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

5.  Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines.

Authors:  Inge H M van Loo; Frits R Mooi
Journal:  Microbiology       Date:  2002-07       Impact factor: 2.777

6.  Temporal trends in circulating Bordetella pertussis strains in Australia.

Authors:  M Poynten; P B McIntyre; F R Mooi; K J Heuvelman; G L Gilbert
Journal:  Epidemiol Infect       Date:  2004-04       Impact factor: 2.451

7.  Severe and unrecognised: pertussis in UK infants.

Authors:  N S Crowcroft; R Booy; T Harrison; L Spicer; J Britto; Q Mok; P Heath; I Murdoch; M Zambon; R George; E Miller
Journal:  Arch Dis Child       Date:  2003-09       Impact factor: 3.791

8.  Trends in pertussis among infants in the United States, 1980-1999.

Authors:  Masahiro Tanaka; Charles R Vitek; F Brian Pascual; Kristine M Bisgard; Jacqueline E Tate; Trudy V Murphy
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

9.  Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK.

Authors:  Erica R Packard; Roger Parton; John G Coote; Norman K Fry
Journal:  J Med Microbiol       Date:  2004-05       Impact factor: 2.472

10.  Pertussis resurgence in Canada largely caused by a cohort effect.

Authors:  Benoît Ntezayabo; Gaston De Serres; Bernard Duval
Journal:  Pediatr Infect Dis J       Date:  2003-01       Impact factor: 2.129

View more
  35 in total

1.  Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method.

Authors:  N K Fry; J Duncan; L Vaghji; R C George; T G Harrison
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-03       Impact factor: 3.267

Review 2.  Bordetella pertussis evolution in the (functional) genomics era.

Authors:  Thomas Belcher; Andrew Preston
Journal:  Pathog Dis       Date:  2015-08-21       Impact factor: 3.166

3.  Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Authors:  Eiji Komatsu; Fuminori Yamaguchi; Akio Abe; Alison A Weiss; Mineo Watanabe
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

4.  Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use.

Authors:  Ewa Mosiej; Ewa Augustynowicz; Monika Zawadka; Waldemar Dabrowski; Anna Lutyńska
Journal:  J Clin Microbiol       Date:  2011-02-09       Impact factor: 5.948

5.  Short-Read Whole-Genome Sequencing for Laboratory-Based Surveillance of Bordetella pertussis.

Authors:  Alex Marchand-Austin; Raymond S W Tsang; Jennifer L Guthrie; Jennifer H Ma; Gillian H Lim; Natasha S Crowcroft; Shelley L Deeks; David J Farrell; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2017-02-22       Impact factor: 5.948

6.  Recovery of Bordetella pertussis from PCR-positive nasopharyngeal samples is dependent on bacterial load.

Authors:  Didrik F Vestrheim; Martin Steinbakk; Martha L Bjørnstad; Amir Moghaddam; Nils Reinton; Mette L Dahl; Nils Grude; Per Sandven
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

7.  Molecular epidemiology of the pertussis epidemic in Washington State in 2012.

Authors:  Katherine E Bowden; Margaret M Williams; Pamela K Cassiday; Andrea Milton; Lucia Pawloski; Marsenia Harrison; Stacey W Martin; Sarah Meyer; Xuan Qin; Chas DeBolt; Azadeh Tasslimi; Nusrat Syed; Ronald Sorrell; Mike Tran; Brian Hiatt; Maria Lucia Tondella
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

8.  Direct molecular typing of Bordetella pertussis from nasopharyngeal specimens in China in 2012-2013.

Authors:  Q Du; X Wang; Y Liu; Y Luan; J Zhang; Y Li; X Liu; C Ma; H Li; Z Wang; Q He
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-05       Impact factor: 3.267

Review 9.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

10.  Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015.

Authors:  Alex-Mikael Barkoff; Jussi Mertsola; Denis Pierard; Tine Dalby; Silje Vermedal Hoegh; Sophie Guillot; Paola Stefanelli; Marjolein van Gent; Guy Berbers; Didrik F Vestrheim; Margrethe Greve-Isdahl; Lena Wehlin; Margaretha Ljungman; Norman K Fry; Kevin Markey; Kari Auranen; Qiushui He
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.